Double-Digit Weight Loss From a Pill: What the New Aleniglipron Trial Results Show

Almost every week, a patient in my clinic asks me the same question: "Is there a pill that works as well as the injections?" For years my honest answer has been "not quite yet." But new data published this year is starting to change that answer, and I think it's worth walking you through it carefully, because it tells us a lot about where obesity treatment is heading — and where it still isn't.

What Is Aleniglipron?

Aleniglipron, also known by its earlier code name GSBR-1290, is an experimental oral medicine that belongs to the GLP-1 receptor agonist family — the same broad class as the injectable drugs semaglutide and tirzepatide that many of you already know. GLP-1 (glucagon-like peptide-1) is a natural hormone your gut releases after eating that signals your brain to feel full, slows down stomach emptying, and helps regulate blood sugar. Drugs in this class mimic that hormone's effect. What makes aleniglipron different is its chemistry: it is a "small-molecule" drug, built as a simple chemical compound rather than a peptide (a small protein-like chain of amino acids). This distinguishes it both from the injectable GLP-1 drugs and from the peptide-based oral GLP-1 tablet already on the market. In practical terms for patients, a small-molecule design is generally easier and cheaper to manufacture and may open the door to more oral options in this drug class over time. Aleniglipron is being developed by Structure Therapeutics.

What Did the Trial Actually Test?

The results I want to share with you come from a randomized, double-blind, placebo-controlled Phase 2b trial — meaning neither patients nor doctors knew who was receiving the real drug versus a placebo (dummy pill) until the study was unblinded, which is the gold standard for reducing bias in a clinical trial. The trial included an open-label extension phase as well, where participants could continue on the drug with everyone aware of what they were taking. It was led by investigators from Northwestern Medicine across 38 medical centers in the United States, and the results were published in the journal Nature Medicine (volume 32, pages 2941–2947) on June 5, 2026. The study enrolled 230 adults living with obesity, or with overweight plus at least one weight-related health condition (such as high blood pressure, high cholesterol, or diabetes). The average participant was 49.8 years old with an average body mass index (BMI) of 39.5 kg/m², which falls in the "severe obesity" range. Participants were randomized to different doses of aleniglipron or to placebo.

What Did the Results Show?

By week 36 of treatment, weight loss was clearly dose-dependent, meaning higher doses produced greater results. At the 45 mg dose, average weight loss was about 9.0%. At the highest dose tested, 120 mg, weight loss ranged from about 11.3% to 12.1% of starting body weight, compared with roughly 0.5% in the placebo group. Once adjusted for the placebo effect, the average difference attributable to the drug was about 11.3 percentage points (95% confidence interval, 8.6% to 13.9%) — a statistical way of expressing how confident the researchers are in the true size of the effect. Looking specifically at the 120 mg group, the trial found that 86% of participants lost at least 5% of their body weight, 70% lost at least 10%, and 38% lost at least 15% by week 36. To put that in perspective, losing even 5–10% of body weight is generally enough to meaningfully improve blood pressure, blood sugar, and joint pain in patients with obesity, so these are clinically meaningful numbers, not just numbers on a scale.

Safety and What We Still Don't Know

As with other GLP-1 medicines, the most common side effects were gastrointestinal: nausea, diarrhea, vomiting, and constipation. Investigators described these as generally mild to moderate in severity, and importantly, they tended to decrease in frequency the longer participants stayed on treatment — a pattern many of my patients on injectable GLP-1 drugs will recognize. About 10.4% of participants stopped the medication because of side effects, which gives you a realistic sense of how tolerable, but not universally tolerable, this drug is. One particularly reassuring finding was that no drug-induced liver injury was observed in the trial, which matters given that the liver already carries a heavy burden in many patients with obesity. That said, I want to be very clear about the limits of this study: this is a Phase 2b trial. It is investigational, not an FDA-approved medicine, and it is not yet available for patients to use. Before any medicine like this reaches the market, it needs to go through larger Phase 3 confirmatory trials involving many more patients over a longer period, to establish long-term safety, durability of weight loss, and how it compares head-to-head with existing treatments.

The Bottom Line

What excites me about this trial isn't just the weight-loss numbers, encouraging as they are — it's what aleniglipron represents. It's one more entry in a fast-growing category of oral, pill-form GLP-1 medicines for obesity, which matters enormously for patients who are hesitant about needles or who simply prefer the convenience of a tablet. We are not at the finish line: this drug still needs to complete Phase 3 trials and regulatory review before it could become available to patients. But as your surgeon, I follow this research closely because it shapes the options I'll be able to offer you in the years ahead, whether that's medication alone, medication alongside surgery, or surgery as the primary treatment. If you're curious about how emerging medicines like this might fit into your own weight-management plan, or how they might complement a bariatric procedure, I'd encourage you to bring it up at your next visit so we can discuss what's right for your specific situation.